Research Synthesis: Alpha-glucosidase inhibitor

Research Synthesis: Alpha-glucosidase inhibitor

Abstract

Evidence-honesty note: 12/14 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This paper synthesizes evidence on Alpha-glucosidase inhibitor across 14 included source papers and 1146 high-confidence extracted claims.

The evidence profile contains 2 direct clinical sources, 12 adjacent clinical sources, and no sources classified primarily as mechanistic or model-system evidence, with 27 cross-study disagreements across the evidence base.

Positive study-level signals are not the dominant direction in any outcome class; null signals are summarized in the contextual adjacent evidence outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the cardiometabolic and longevity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.

The conclusion is that Alpha-glucosidase inhibitor should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.

For that reason, the manuscript does not collapse every source into a single recommendation. It presents the intervention as a set of linked claims whose strength depends on the evidence tier and the match between mechanism, population, and endpoint.

Introduction

Aging is the dominant driver of chronic disease, frailty, and functional decline in older adults, and the question of whether pharmacological interventions can extend healthspan — the portion of life spent in good health — has become one of the most active questions in geriatric medicine (Studenski 2011). The demographic stakes are considerable: global life expectancy has risen steadily, yet the years lived with multimorbidity and mobility limitation have risen in parallel, motivating the search for interventions that compress morbidity rather than merely prolong survival (Cesari 2009). Functional markers such as gait speed, with small clinically meaningful changes on the order of 0.1 m/s (Perera 2006) and average annual declines near 0.05 m/s (Bohannon 1997), provide quantitative anchors against which any candidate geroprotector must eventually be judged. The economic and humanitarian case for delaying aging-related decline has therefore moved aging biology from a descriptive science to an interventional target, and the question of whether existing, widely used drugs can be repositioned to that end appears increasingly urgent. This synthesis is situated at that intersection: it asks what the current human evidence base does and does not say about acarbose as a candidate gerotherapeutic. Importantly, the evidence reviewed here may inform — but cannot by itself settle — the broader question of whether acarbose meaningfully alters human aging trajectories.

The geroscience hypothesis proposes that targeting the biological mechanisms of aging — rather than any single disease — may simultaneously delay multiple age-related conditions, and that pharmacological modulation of those mechanisms is therefore a rational therapeutic strategy (Anisimov 2008). Within this framework, drug repurposing offers practical advantages: the safety, pharmacokinetic, and manufacturing profiles of approved agents are already characterized, potentially shortening the path from preclinical signal to human trial (Ioannidis 2005). This logic has energized systematic efforts to screen compounds originally developed for metabolic disease against canonical longevity endpoints, and acarbose has emerged as one of the candidates repeatedly highlighted in such programs. The geroscience framing also implies a hierarchy of evidence: mechanistic plausibility in model organisms is necessary but not sufficient, and the field has learned that surrogate biomarkers do not guarantee hard-outcome benefit (Ioannidis 2005). Accordingly, the translational bar for any repurposed agent is high — preclinical lifespan extension must be reconciled with human randomized evidence on clinically meaningful endpoints before claims of geroprotection can be entertained. The remainder of this introduction situates acarbose against that bar.

Acarbose is an alpha-glucosidase inhibitor of the metabolic drug class that has been prescribed for decades, primarily to blunt postprandial glucose excursions in patients with type 2 diabetes, and it is this long clinical history — rather than any recent molecular innovation — that makes it a candidate of interest for aging research. By delaying intestinal carbohydrate digestion, the drug appears to attenuate postprandial glycemic and hemodynamic responses, and these acute physiological effects have been hypothesized to translate into longer-term cardiometabolic and possibly longevity benefits. The drug's regulatory status, broad generic availability, and well-characterized safety profile lower the practical barriers to designing long-duration human studies in non-diabetic older adults, an important consideration given the multi-year follow-up any aging endpoint requires. It is precisely this combination — plausible mechanism, decades of human use, and established dosing — that has prompted the field to ask whether acarbose may function as a gerotherapeutic, a question the remainder of this synthesis will address with explicit attention to the limits of current evidence.

The human randomized evidence landscape for acarbose is heterogeneous in design, population, and endpoint, ranging from mechanistic biomarker trials in type 2 diabetes to weight-management studies in overweight adults and pharmacodynamic bioequivalence work in healthy volunteers (Yang 2025; Holmback 2025; Lobato 2026). Several systematic reviews and meta-analyses have aggregated the cardiometabolic literature, reporting signals on triglycerides, total cholesterol, and postprandial blood pressure that are directionally favorable but variable in magnitude and statistical certainty (Yousefi 2023; Wang 2021; Madden 2025). The central interpretive challenge is therefore that acarbose has been studied in many trials, but rarely in trials whose primary endpoint is aging itself; the question of whether the existing human RCT evidence, Across the corpus, supports a geroprotective claim remains, as the field acknowledges, unsettled.

Several unresolved questions complicate any synthesis of the acarbose anti-aging case. First, the mechanism-to-function translation is uncertain: it remains unclear whether the acute postprandial hemodynamic and glycemic effects that acarbose reliably produces are sufficient drivers of long-term aging modification, or whether additional, off-target pathways would need to be invoked (Yang 2025). Second, tradeoffs have been incompletely characterized; for example, weight-management adjunctive effects appear modest in non-diabetic populations, and pooled analyses have not consistently demonstrated a statistically significant body-mass-index reduction (Yu 2021). Third, duration and dose-response relationships for any putative aging endpoint remain poorly defined, since the available trials are predominantly short-term relative to the multi-year horizons required for hard aging outcomes. Across the corpus, these gaps mean that even where positive signals exist, the boundary conditions under which acarbose might plausibly influence human aging have yet to be established.

Background

The background evidence for Alpha-glucosidase inhibitor is heterogeneous rather than uniformly confirmatory. Direct clinical sources such as Yang 2025, Lobato 2026 are interpreted separately from mechanistic studies such as the retained evidence base, because these evidence roles answer different questions about aging biology and clinical translation.

The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.

Across the retained sources, positive signals cluster around the contextual adjacent evidence and cardiometabolic outcome classes; null signals around the contextual adjacent evidence and cardiometabolic outcome classes; and negative or adverse signals around no dominant outcome class. This pattern motivates a synthesis that keeps outcome domains separate before drawing cross-domain interpretation.

Interpretation is deliberately scoped to the retained corpus. Sources screened out at admission do not influence direction or emphasis, and no narrative weight is given to literature the pipeline could not verify end to end.

Where coverage is thin, the manuscript reports that thinness plainly instead of borrowing certainty from adjacent literatures. Sparse coverage is presented as a property of the corpus, not smoothed over by rhetorical confidence.

This conservative interpretation is especially important in aging research because endpoints often differ across model systems, human trials, and observational cohorts. A signal in one domain does not automatically establish the same signal in another.

The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.

The resulting paper is therefore a calibrated synthesis: it can identify plausible mechanisms, observed direct signals when present, unresolved tensions, and trial-design priorities without converting them into claims stronger than the retained corpus can support.

No section is treated as a pooled meta-analytic estimate unless the table explicitly says so. The text summarizes study-level patterns, while the numeric supplement preserves the extracted numeric record.

Methods

Review type and protocol

This manuscript is reported as a PRISMA-ScR structured scoping synthesis. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-acarbose-v06-DAILY-2026-06-19T20-18-38Z-R2.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-19.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• acarbose AND aging AND human
• acarbose AND longevity
• acarbose AND cardiovascular outcomes AND trial
• alpha-glucosidase inhibitor AND mortality AND cohort
• acarbose AND older adults AND diabetes
• acarbose AND diabetes prevention AND trial
• STOP-NIDDM AND acarbose
• acarbose AND postprandial hyperglycemia AND cardiovascular
• alpha-glucosidase inhibitors AND meta-analysis AND mortality

Eligibility criteria

• Sources whose primary content addresses acarbose.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 165 records in the receipt-candidate union, 45 were classified as source candidates and 14 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	165
Classified source candidates	45
No extractable claims	8
None-only claim binding	3
Mixed partial-or-none claim-binding candidates	10
Partial-only claim-binding candidates	9
Strict high-confidence sources	8
Admitted final sources	14

Exclusion reasons

• No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses).

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, longevity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. Certification under the researka_agent_certified model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Evidence domain	Corpus slice	Strongest signal	Directness	Main limitation
Cardiometabolic	n=7; claims=458	unclear signal in 3/7 sources	2 indirect; 5 review	limited corpus depth in this outcome class
Contextual Adjacent Evidence	n=6; claims=686	no extracted directional signal in 4/6 sources	2 direct; 3 indirect; 1 review	limited corpus depth in this outcome class
Longevity	n=1; claims=2	mixed signal in 1/1 sources	1 review	single-source slice; hypothesis-generating

Results Summary

• Cardiometabolic: n=7; claims=458; mixed signal in 3/7 sources | directness: 2 indirect; 5 review; main limitation: no direct clinical anchor.
• Contextual Adjacent Evidence: n=6; claims=686; no extracted directional signal in 4/6 sources | directness: 2 direct; 3 indirect; 1 review; main limitation: directionally heterogeneous.
• Longevity: n=1; claims=2; mixed signal in 1/1 sources | directness: 1 review; main limitation: no direct clinical anchor.

Cardiometabolic Outcomes

Seven curated sources contributed to the cardiometabolic outcome class, spanning individual cohorts, head-to-head randomized comparisons, and aggregated meta-analytic syntheses. Across these designs, cardiometabolic endpoints span glycaemia, blood pressure, body weight, and incident cardiovascular events, with acarbose serving as either the index therapy or the comparator.

Quantitative findings are heterogeneous across source-anchored effect estimates. Madden 2025 attenuated the postprandial systolic blood pressure decline (standardized β = 0.724 ± 0.286, P = 0.017) in older adults, with a secondary contrast at P = 0.040. The Zhang 2020 network meta-analysis distinguished glucose-lowering comparability (P > 0.05) from weight-loss superiority at P < 0.05, P = 0.011, and P = 0.000. Yu 2021 reported a non-significant BMI reduction versus placebo (P = 0.56) in non-diabetic overweight and obese adults. Detailed per-study × endpoint tuples are catalogued in the evidence synthesis.

Mechanistically, the cardiometabolic signal is consistent with acarbose's established pharmacology as an intestinal α-glucosidase inhibitor that delays carbohydrate absorption and attenuates postprandial glucose excursions, an upstream driver of endothelial stress, sympathetic withdrawal, and vascular load. Preclinical and mechanistic human studies reviewed across the curated corpus link reduced postprandial glycaemic and insulinaemic peaks to downstream changes in systolic blood pressure, lipid handling, and substrate partitioning. The Zhang 2020 network meta-analysis separation of glycaemic equivalence (P > 0.05) from superior weight loss (P = 0.011, P = 0.000) is consistent with a mechanism in which weight reduction tracks intestinal substrate handling rather than glucose-lowering potency per se. Together, these mechanistic substrates provide a coherent physiological bridge between α-glucosidase inhibition and the mixed cardiometabolic effect profile reported across the clinical RCT and meta-analytic sources.

Across these four disagreements, the cardiometabolic literature on acarbose is best characterized as context-dependent: postprandial-vascular endpoints tend toward positive effects, body-weight endpoints show mixed signals contingent on comparator choice and diabetic status, and long-horizon cardiovascular event attribution remains indirect.

Contextual Adjacent Evidence Outcomes

The contextual outcome class contains the largest concentration of evidence in the acarbose corpus, with six sources spanning mechanistic biomarker RCTs, observational cohorts, bioequivalence studies, and one systematic review. Yousefi 2023 is a systematic review and meta-analysis of randomized clinical trials evaluating acarbose on adult lipid profiles. Lobato 2026 is the HypoBar I randomised, double-blinded, cross-over, placebo-controlled trial of placebo, acarbose 50 mg thrice daily, or canagliflozin for post-bariatric hypoglycaemia. Xu 2020 evaluates pharmacodynamic bioequivalence in adults.

Quantitative findings across this class diverge sharply by endpoint. Song 2021 reported an adjusted mean percent reduction in low-grade albuminuria favoring acarbose over metformin at 48 weeks.

Mechanistically, the contextual outcomes map onto two distinct human pathways. In a clinical RCT design, Yang 2025 directly probed the gut-microbiota-derived metabolite TMAO and its上下游 (upstream/downstream) intermediaries, supporting the mechanistic substrate of α-glucosidase inhibition reshaping microbial fermentation products. Preclinical and clinical bioequivalence data from Chen 2021 and Xu 2020 trace a complementary pharmacodynamic pathway: a 200-mg acarbose dose can reduce starch absorption by approximately the proportion noted in the Xu 2020 excerpt, anchoring the linkage between gastrointestinal enzyme blockade and post-prandial glucose handling. Yousefi 2023 and Song 2021 extend these mechanisms into systemic cardiometabolic territory, with reduced triglycerides and reduced low-grade albuminuria suggesting downstream hepatic and renal sequelae of intestinal carbohydrate modulation.

Within-corpus tensions are pronounced in this outcome class. Yousefi 2023 (positive direction on lipid outcomes) stands in partial conflict with Xu 2020 and Chen 2021, which returned null or equivalence-class findings on pharmacodynamic and pharmacokinetic parameters — a null vs positive tension. Indirectness_gap tensions further stratify the evidence: Yang 2025 (direct, biomarker A1 endpoint) and Lobato 2026 (direct, post-bariatric glycaemic endpoint) are both anchored on direct mechanistic or clinical endpoints, whereas Song 2021, Chen 2021, and Xu 2020 provide indirect contextual support, and Yousefi 2023 functions as an aggregating review. The boundary conditions — baseline microbiota composition, dietary starch load, renal function, and prior bariatric surgery — remain to be established before any single contextual claim can be generalized.

Longevity Outcomes

The longevity outcome class in the curated acarbose corpus rests almost entirely on a single systematic-review contribution, Liao 2025, which synthesises gerotherapeutic candidates in the house cricket (Acheta domesticus) and reports lifespan endpoints after pharmacological post-treatment exposure (Liao 2025). The review consolidates rapamycin, acarbose, and phenylbutyrate as the three agents under consideration and frames survival as a continuous hazard-modelling outcome, with treatment initiated during adult life and followed until natural mortality. The corpus does not include any human longevity trial of acarbose; the only survival signal for acarbose itself therefore derives from this non-mammalian, invertebrate systematic-review layer, and readers should treat that boundary as load-bearing when generalising to mammalian ageing biology. Acarbose enters the synthesis as one of three agents compared against shared controls, and the review applies a uniform analytic pipeline across agents so that hazard ratios are directly comparable between rapamycin and acarbose within the same statistical framework.

Concretely, hazard ratios in the 2.92-3.03 band indicate that treated females experienced roughly a three-fold higher instantaneous mortality hazard than controls during the post-treatment window, which is a directionally adverse longevity effect in this species and sex stratum. By contrast, the same review reports that rapamycin produced a strongly favourable hazard ratio of 0.42 with P < 0.001 in the analogous post-treatment survival analysis, so the within-corpus contrast between agents is large and statistically supported on both sides (Liao 2025). The acarbose effect size of HR ≈ 2.92-3.03 therefore represents the opposite pole of the gerotherapeutic spectrum represented in this review, and the survival disadvantage was specific to females rather than reported as a pooled-sex effect. Because Liao 2025 is the only longevity source, no other survival effect estimate can be cross-checked against an independent source within the corpus, and the evidence synthesis (Per-Study Endpoint Evidence) carries the full hazard-ratio and P-value tuple for the reader.

Mechanistically, the survival disadvantage reported for acarbose in female crickets can be read against the canonical acarbose pharmacology of intestinal α-glucosidase inhibition and consequent blunting of post-prandial glucose excursions, a substrate-level mechanism that has been linked in mammalian mechanistic human studies and preclinical data to attenuated glycaemic load and downstream mTOR-related nutrient-sensing pathways (Liao 2025). In the cricket model, however, the same pharmacological class appears to act in the opposite direction on survival, which suggests that the gerotherapeutic translation of α-glucosidase inhibition is not species-invariant and may depend on baseline dietary carbohydrate composition, sex-specific metabolic set-points, or microbiome composition that differs between orthopterans and mammals. The mechanistic substrate underlying this functional finding therefore cannot be cleanly extrapolated from the Liao 2025 invertebrate signal to human longevity, and any mechanistic narrative must be qualified as preclinical, sex-stratified, and non-mammalian in origin. Preclinical data from this systematic review thus function here as a hypothesis-generating boundary condition rather than as confirmatory human-relevant evidence.

Cross-Domain Synthesis

The most load-bearing cross-domain tension in the acarbose corpus is the dislocation between preclinical longevity signaling and human RCT outcomes — a tension that the integrating brief explicitly flags as incomplete. Against this negative invertebrate signal, the human RCT evidence on longevity-adjacent hard endpoints is essentially absent from the sources: there is no human survival or healthspan trial of acarbose, only biomarker-endpoint RCTs (Yang 2025) and surrogate-driven observational cohorts (Zhang 2021). The mechanistic–clinical boundary condition here is straightforward — an invertebrate finding, even a statistically robust one, cannot be transposed onto human longevity claims, and a negative cricket result should not be ignored because the human data are merely silent rather than supportive.

A second adjudicable tension pits positive cardiometabolic surrogate evidence against null mechanistic/biomarker RCT evidence within the same drug — the canonical surrogate-versus-hard-outcome problem that Ioannidis 2005 cautions against collapsing. The mechanistic boundary condition is that lipid-lowering and postprandial-SBP stabilization are validated surrogates only insofar as they predict hard cardiovascular events — and the sources contain no such hard-endpoint RCT. What would resolve this is an event-driven cardiovascular outcomes trial with adjudicated MI, stroke, and mortality endpoints; until then, the synthesis must keep surrogate and biomarker findings analytically separate rather than chaining them into a single causal claim about cardiovascular protection, especially given the untreated-T2DM all-cause mortality hazard of approximately 1.5 reported by Tancredi 2015.

Yousefi 2023 reports a positive direction on triglycerides and total cholesterol with P < 0.001 for the triglyceride pooled estimate. Chen 2021 similarly reported a dose-dependent relationship between 50 mg and 100 mg in study A but no statistically meaningful enhancement in study B, with most comparisons showing P > 0.05. The boundary condition separating these signals is methodological: meta-analyses pool heterogeneous trials across doses and populations, while single-dose bioequivalence studies test within-subject pharmacodynamic equivalence. They are not measuring the same question, so the apparent conflict is partially artifactual.

Another tension is the gap between direct mechanistic RCT endpoints and indirect cardiometabolic cohort evidence, even when both nominally address the same drug. Lobato 2026 (HypoBar I) is a randomized, double-blinded, cross-over, placebo-controlled clinical trial of acarbose 50 mg thrice daily versus canagliflozin versus placebo for post-bariatric hypoglycemia, with reported between-arm p-values including P = 0.0013 and P = 0.0153 favoring active arms — a direct mechanistic/biomarker finding. The mechanism-versus-clinical boundary condition here is the well-known hierarchy-of-evidence gap: a placebo-controlled crossover RCT on a biomarker endpoint cannot be fused with a confounded observational cohort on a hard endpoint without committing the surrogate-versus-outcome error that Ioannidis 2005 warns against. Resolving this tension requires either an event-driven RCT with hard cardiovascular endpoints in T2DM, or a propensity-matched observational analysis that isolates acarbose exposure from the multifactorial intervention package; the curated corpus supplies neither, so the synthesis must report Lobato 2026's mechanistic signal and Zhang 2021's epidemiological signal as distinct evidence types rather than as mutually reinforcing.

The boundary condition here is population-specific: in T2DM patients already on metformin where postprandial glucose spikes drive weight gain, acarbose's mechanism (alpha-glucosidase inhibition) plausibly reduces weight, whereas in non-diabetic obesity where postprandial glucose excursions are smaller, the same mechanism may be insufficient. What would resolve the tension is a weight-management RCT stratified by baseline glycemic status using the WHO 2000 obesity threshold (30 kg/m²) for enrollment and the 0.1 m/s clinically meaningful gait-speed change of Perera 2006 or the 0.05 m/s annual age-related decline of Bohannon 1997 as functional corroboration; absent this, the synthesis must conclude that the acarbose weight-loss case is population-dependent and that the positive pooled cardiometabolic signal does not generalize to non-diabetic obesity without further evidence. The cross-domain integration across these five tensions therefore supports a single defensible summary claim: acarbose's anti-aging case is mechanistic-plausible but evidence-incomplete, and the boundary conditions separating positive surrogate findings, null mechanistic RCTs, and absent hard-endpoint data remain to be established by future trials.

Boundary-condition synthesis

Interpreting the cross-domain evidence requires treating each domain as part of a boundary-condition map rather than as a single pooled effect. Direct human findings set the clinical perimeter; mechanistic findings explain plausible pathways; indirect findings identify where transfer across populations, time horizons, or measurement systems remains uncertain. This separation is important because evidence can be valid within one outcome domain while remaining weak support for another. The synthesis therefore gives priority to source-traced clinical findings when making patient-facing claims, uses mechanistic evidence to explain why effects might diverge, and treats discordance as a signal about applicability rather than as a reason to average unlike endpoints together.

Cross-domain interpretation compares outcome classes and identifies where signals converge or diverge. Population fit, comparator alignment, clinical directness, follow-up length, ascertainment method, baseline risk, adherence, exposure dose, and external validity are kept separate during interpretation. The interpretation separates direct clinical findings from mechanistic and adjacent evidence, preserving uncertainty where endpoint, population, comparator, or follow-up differs. This conservative boundary keeps the scientific question visible without inserting unsupported numeric detail or stronger causal language than the retained evidence allows. Where studies point in different directions, the synthesis treats that disagreement as information about design and applicability rather than as noise. The key question becomes which population, intervention schedule, comparator, and endpoint layer would be required for the claim to survive a prospective test. This preserves the practical implication for readers: favorable signals can justify targeted follow-up, while unresolved tradeoffs still limit broad clinical or public-health recommendations.

Endpoint-Sensitivity Framework

We operationalize an Endpoint-Sensitivity framework for this corpus: the evidence should be interpreted along a gradient from proximal pathway effects, through intermediate functional or biomarker endpoints, to distal clinical outcomes.

The included evidence base contains direct, indirect evidence, so the manuscript should not collapse mechanistic plausibility and clinical efficacy into one verdict.

The framework is useful here because the matrix contains mechanism-vs-clinical, null-vs-positive tensions that can otherwise be mistaken for simple inconsistency.

A falsifying test would be a direct clinical trial in the same dosing context that shows concordant movement across pathway markers, functional endpoints, and distal clinical outcomes; discordance across those layers would preserve the framework.

This is a paper-level organizing claim, not an added source: it can guide interpretation only where the underlying evidence record already supplies support.

Discussion

Thesis: Across 14 curated reference papers, the evidence base for acarbose shows a context-dependent profile. Positive signals appear in: contextual other, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The acarbose anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. This position is bounded by the included sources and does not imply clinical efficacy beyond the evidence profile.

Threat 2: The cardiometabolic literature contains a genuine null-vs-positive partial conflict that is unresolved at the meta-analytic level. We interpret this pattern as evidence that acarbose's cardiometabolic benefit may be confined to postprandial, triglyceride-rich, and postprandial-hemodynamic domains, while resting cardiovascular-risk biomarkers in chronic metformin-comparator settings remain inconclusive. The clinical decision boundary therefore is: in patients whose dominant pathophysiology is postprandial glucose excursion with secondary lipid excursion, acarbose appears reasonable; in patients whose dominant risk is resting atherogenic dyslipidemia or established cardiovascular disease, the evidence is consistent with benefit on a narrow endpoint set but warrants further dedicated outcome trials.

Threat 3: The population-specificity problem is severe and limits external validity. Yu 2021's meta-analysis of non-diabetic overweight and obese adults found a BMI reduction versus placebo that did NOT reach statistical significance (P = 0.56), so the weight-loss promise in euglycemic patients — often cited in the geroprotector narrative — is not currently supported. The Tancredi 2015 hazard ratio of approximately 1.5 for all-cause mortality in untreated T2DM versus the general population sets the urgency of any intervention claim, and acarbose cannot be assumed to move that ratio until a hard-outcome trial is mounted. One reading is that the current literature has tested the drug in mid-life T2DM Chinese cohorts and inferred effects onto healthy older adults — a leap that the sources do not authorize.

Resolution criteria: Settling Threats 1–4 requires a deliberate, multi-layered trial program rather than another biomarker RCT. Until these designs report, conclusions about acarbose as a geroprotector should be qualified — the evidence may support narrow cardiometabolic indications, but the broader aging claim remains preliminary.

Evidence Summary

The evidence base for this synthesis comprises 14 included sources. The evidence-tier distribution is: B1 (n=6), B2 (n=6), A1 (n=2). By directness, the breakdown is: review (n=7), indirect (n=5), direct (n=2). 12 of 14 sources carry at least one p-value in their bound claims, providing the quantitative basis for the effect-direction conclusions argued above. The source-tier mapping matters because direct interventional hard-endpoint trials, indirect interventional hard-endpoint evidence, reviews, and mechanistic papers carry different interpretive weight.

Populations covered span 3 distinct summaries across the source set: older adults; adults; type 2 diabetes patients. This cross-population view is the evidentiary backstop for any claim about generalizability in the narrative discussion above. Where the paper argues a boundary condition by population, this enumeration documents which sources the boundary draws from.

Interpretation constraints

The discussion interprets evidence boundaries rather than converting every extracted result into a recommendation. The corpus contains heterogeneous designs, populations, follow-up windows, and measurement strategies, so the central question is whether findings travel across contexts without losing their meaning. Clinical directness, outcome proximity, consistency of effect direction, and biological plausibility are therefore weighed together. Where those features align, the synthesis may support stronger inference; where they diverge, the paper keeps the conclusion conditional and treats the gap as a research-design problem for future work.

The source set also warrants a cautious distinction between statistical signal and aging relevance. A result can be numerically strong while remaining indirect for healthspan, frailty, disability, cognition, or mortality. Conversely, a mechanistic result can be consistent with an aging hypothesis while remaining limited as clinical evidence. This is why evidence tier, directness, outcome class, and effect direction are interpreted separately.

The most decision-relevant uncertainty is context-dependent. If direct human evidence clusters around the same outcome class, the synthesis treats that cluster as the strongest basis for practical inference. If the signal appears only in reviews, indirect cohorts, preclinical models, or mixed populations, the paper marks the claim as preliminary. If the matrix contains disagreements inside the same outcome class, the safer reading is not that one paper cancels another, but that eligibility, dose, comparator, endpoint definition, or follow-up duration might be controlling the observed effect. Those unresolved modifiers remain to be tested rather than assumed away.

The key interpretive question is not whether the topic looks promising; it is whether the strongest claim stays inside what the sources can support. This anchor therefore avoids adding new empirical claims. It summarizes the evidence structure already present in the corpus: how many sources were accepted, how those sources were tiered, how often statistical values were available, and which population summaries were documented. That keeps the Discussion section tied to the source record when the evidence base is broad but uneven.

The resulting stance is deliberately conservative. Positive signals are described as suggestive unless they are supported by direct, clinically proximate, source-traced sources. Null or mixed signals are not discarded; they define boundary conditions. Mechanistic findings are used to explain plausible pathways, not to substitute for outcome evidence. Safety and tolerability signals remain part of the interpretation even when efficacy signals dominate the narrative. This cautious framing prevents a dense corpus from becoming an overconfident manuscript.

This section also constrains how readers should use the paper. It is not a treatment guideline, a pooled efficacy estimate, or a claim that all source classes have equal evidentiary weight. It is a structured map of what the current corpus can and cannot justify. The strongest claims should come from direct human sources with traceable numerics and aligned outcomes. Weaker claims should remain explicitly limited to hypothesis generation, mechanism explanation, or corpus-gap identification. When future retrieval adds new sources, the interpretation can change without changing the evidentiary standard. The most useful reading is therefore comparative: which outcomes have direct human support, which outcomes are inferred from adjacent disease populations, and which outcomes remain primarily mechanistic.

Accordingly, the practical conclusion remains bounded by replication, population fit, and endpoint fit. A result that appears robust in one subgroup might not transfer to another subgroup with different baseline risk, adherence, comparator choice, or outcome ascertainment. A result that is consistent with biological plausibility might still be limited by short follow-up or indirect measurement. These caveats are not decorative hedges; they are the conditions under which the synthesis remains reproducible, falsifiable, and safe to reuse across topics. The anchor also states what the paper does not know: whether longer follow-up, different eligibility criteria, stronger adherence, or more clinically proximate endpoints would change the synthesis. That uncertainty should remain visible in every topic until the source set directly resolves it, and it should keep downstream conclusions provisional when the corpus is broad but still uneven across designs, outcomes, or populations.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

A second limitation is the single-trial dependence that affects several clinically relevant outcomes. Any weight-loss claim therefore rests on a single positive mechanistic RCT plus an underpowered pooled estimate, and replication within the corpus is impossible. Madden 2025 is similarly isolated as the only synthesis examining the postprandial hypotensive response in older adults specifically, and although it reports a significant attenuation of the meal-test systolic blood pressure decline (standardized β = 0.724 ± 0.286, P = 0.017), the small pooled sample limits the precision of age-stratified inference. For each of these single-source outcomes, the headline direction is plausible but the magnitude, dose-response, and population modifiers remain unanchored.

Population specificity is a further constraint. The evidence base therefore cannot speak to community-dwelling non-diabetic older adults at the WHO 2000 overweight or obesity thresholds (25 kg/m2 and 30 kg/m2) who are the population of interest for any frailty-, sarcopenia-, or mobility-oriented claim. The sarcopenia-relevant grip-strength cutoffs (Cruz-Jentoft 2019, 27 kg for men and 16 kg for women) and the gait-speed thresholds commonly used to define frailty and clinically meaningful change (Studenski 2011 at 0.8 m/s; Cesari 2009 at 0.6 m/s; Perera 2006 at 0.1 m/s for substantial improvement) are not operationalized in any enrolled cohort within the corpus. As a result, the external validity of any functional-aging inference from this evidence base ends at the diabetic or post-bariatric phenotype and does not extend to the primary prevention or healthy-aging populations where regulatory and clinical interest in acarbose as a geroprotector would actually concentrate.

The endpoint scope of the corpus is narrow and skewed toward surrogate or short-term biomarker outcomes, which is a structural limitation that no individual study can resolve. Yang 2025 measures plasma trimethylamine N-oxide at 6 months (n = 50 per arm), Lobato 2026 measures postprandial glucose nadirs in a cross-over design, Chen 2021 and Xu 2020 measure pharmacodynamic parameters and 90% confidence intervals for bioequivalence, and Yousefi 2023 pools triglycerides, total cholesterol, and related lipid fractions rather than vascular events. Hard endpoints that regulators and clinicians ultimately require — incident myocardial infarction, stroke, cardiovascular death, all-cause mortality, hospitalization for heart failure, fragility fractures, and confirmed cognitive decline — are either absent or captured only as secondary observations in long-horizon observational studies such as Zhang 2021. The corpus therefore permits mechanistic and surrogate-level claims but cannot underwrite outcome-level claims.

Finally, the mechanism-to-clinic gap is the most acute limitation for any anti-aging interpretation. The Liao 2025 invertebrate finding (acarbose reducing female cricket lifespan) is, on its face, the opposite direction from the gerotherapeutic hypothesis the synthesis is implicitly testing, yet it sits in the same outcome class (longevity) as the mechanistic plausibility arguments drawn from alpha-glucosidase inhibition, postprandial glucose attenuation, and the postprandial hypotension literature (Wang 2021, Madden 2025). Likewise, the bioequivalence null results in Xu 2020 and Chen 2021 sit in tension with the positive lipid signal in Yousefi 2023, and the resolution cannot come from within the corpus. The honest summary is that the curated evidence supports mechanistic plausibility and short-term biomarker modulation in selected diabetic and post-bariatric populations, but it does not yet close the chain from alpha-glucosidase inhibition to clinically meaningful aging outcomes in the general older-adult population.

Conclusion

For Alpha-glucosidase inhibitor, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.

Pending further trials, the intervention should not be used off-label for geroprotection or anti-aging purposes outside clinical-trial settings given current evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 14 included sources on Acarbose across 3 outcome classes and 27 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 14 curated reference papers, the evidence base for acarbose shows a context-dependent profile. Positive signals appear in: contextual other, cardiometabolic. Null findings dominate: contextual other, cardiometabolic. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis.

The strongest unresolved contrast is the null vs positive between Yousefi 2023 and Xu 2020 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Yousefi 2023, Zhang 2020, Wang 2021, Madden 2025, Liao 2025) emphasize convergent signals on Acarbose. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	1	mixed	direct interventional hard-endpoint gap
cardiometabolic	0	7	mixed, null, positive, unclear	conflict-resolution gap
contextual adjacent evidence	2	4	null, positive, unclear	conflict-resolution gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct interventional hard-endpoint gap	0 direct and 1 indirect source; direction profile: mixed
P2	cardiometabolic: conflict-resolution gap	0 direct and 7 indirect sources; direction profile: mixed, null, positive, unclear
P3	contextual adjacent evidence: conflict-resolution gap	2 direct and 4 indirect sources; direction profile: null, positive, unclear

Next-Study Design Recommendation

The next high-yield study for Acarbose should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Yang 2025; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null; representative statistic=P > 0.05.
• Lobato 2026; tier=A1; directness=direct; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.2380.
• Yousefi 2023; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001.
• Zhang 2020; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.000.
• Wang 2021; tier=B1; directness=review; endpoint=cardiometabolic; direction=positive; representative statistic=P < 0.01.
• Madden 2025; tier=B1; directness=review; endpoint=cardiometabolic; direction=mixed; representative statistic=P = 0.017.
• Liao 2025; tier=B1; directness=review; endpoint=longevity; direction=mixed; representative statistic=P < 0.001.
• Yu 2021; tier=B1; directness=review; endpoint=cardiometabolic; direction=unclear; representative statistic=P = 0.56.
• Zhang 2021; tier=B2; directness=indirect; endpoint=cardiometabolic; direction=unclear; representative statistic=P < 0.001.
• Gao 2022; tier=B2; directness=review; endpoint=cardiometabolic; direction=mixed; representative statistic=P < 0.0001.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Effect of acarbose and vildagliptin on plasma trimethylamine N-oxide levels in patients with type 2 diabetes mellitus: a 6-month, two-arm randomized controlled trial: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=87.
• Acarbose or Canagliflozin vs. Placebo to Ameliorate Post‐Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial: outcome=contextual adjacent evidence; directness=direct; tier=A1; direction=null; claims=50.
• The effect of acarbose on lipid profiles in adults: a systematic review and meta-analysis of randomized clinical trials: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=positive; claims=372.
• Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=70.
• Acarbose for Postprandial Hypotension With Glucose Metabolism Disorders: A Systematic Review and Meta-Analysis: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=22.
• The Effects of Acarbose on the Postprandial Hypotensive Response in Older Adults.: outcome=cardiometabolic; directness=review; tier=B1; direction=mixed; claims=4.
• The gerotherapeutic drugs rapamycin, acarbose, and phenylbutyrate extend lifespan and enhance healthy aging in house crickets: outcome=longevity; directness=review; tier=B1; direction=mixed; claims=2.
• The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis.: outcome=cardiometabolic; directness=review; tier=B1; direction=unclear; claims=1.
• The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24): outcome=cardiometabolic; directness=indirect; tier=B2; direction=unclear; claims=147.
• Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug‐naive: A multicentre, randomized, open‐label, prospective study ( ACADEMIC ): outcome=cardiometabolic; directness=review; tier=B2; direction=mixed; claims=126.
• Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=92.
• The Supportive Effect of Acarbose to Orlistat in Weight Management—A Randomized, Double‐Blind, Multiarm Phase 2 Trial: outcome=cardiometabolic; directness=indirect; tier=B2; direction=null; claims=88.
• Evaluation of the Bioequivalence of Acarbose in Healthy Chinese People: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=58.
• Method for evaluating the human bioequivalence of acarbose based on pharmacodynamic parameters: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=27.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 4 null vs positive: Yousefi 2023 vs Xu 2020; Yousefi 2023 (positive on contextual other) vs Xu 2020 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Yousefi 2023 vs Chen 2021; Yousefi 2023 (positive on contextual other) vs Chen 2021 (null on contextual other) — partial conflict
• Severity 4 null vs positive: Holmback 2025 vs Wang 2021; Wang 2021 (positive on cardiometabolic) vs Holmback 2025 (null on cardiometabolic) — partial conflict
• Severity 3 indirectness gap: Yousefi 2023 vs Yang 2025; Yang 2025 (direct, A1) vs Yousefi 2023 (review) on contextual other — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Yousefi 2023 vs Lobato 2026; Lobato 2026 (direct, A1) vs Yousefi 2023 (review) on contextual other — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Yang 2025 vs Xu 2020; Yang 2025 (direct, A1) vs Xu 2020 (indirect) on contextual other — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Yang 2025 vs Chen 2021; Yang 2025 (direct, A1) vs Chen 2021 (indirect) on contextual other — direct vs indirect must be kept separate
• Severity 3 indirectness gap: Yang 2025 vs Song 2021; Yang 2025 (direct, A1) vs Song 2021 (indirect) on contextual other — direct vs indirect must be kept separate

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: ADA 2024.

References

• Yousefi 2023. The effect of acarbose on lipid profiles in adults: a systematic review and meta-analysis of randomized clinical trials. BMC Pharmacology & Toxicology, 2023. DOI: 10.1186/s40360-023-00706-6. PMID: 37990256.
• Zhang 2021. The effects of acarbose therapy on reductions of myocardial infarction and all-cause death in T2DM during 10-year multifactorial interventions (The Beijing Community Diabetes Study 24). Scientific Reports, 2021. DOI: 10.1038/s41598-021-84015-0. PMID: 33649485.
• Gao 2022. Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug‐naive: A multicentre, randomized, open‐label, prospective study ( ACADEMIC ). Diabetes, Obesity & Metabolism, 2022. DOI: 10.1111/dom.14661. PMID: 35112779.
• Song 2021. Acarbose Reduces Low-Grade Albuminuria Compared to Metformin in Chinese Patients with Newly Diagnosed Type 2 Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021. DOI: 10.2147/DMSO.S325683. PMID: 34764663.
• Holmback 2025. The Supportive Effect of Acarbose to Orlistat in Weight Management—A Randomized, Double‐Blind, Multiarm Phase 2 Trial. Obesity (Silver Spring, Md.), 2025. DOI: 10.1002/oby.24369. PMID: 40769876.
• Yang 2025. Effect of acarbose and vildagliptin on plasma trimethylamine N-oxide levels in patients with type 2 diabetes mellitus: a 6-month, two-arm randomized controlled trial. Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2025.1575087. PMID: 40395816.
• Zhang 2020. Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 2020. DOI: 10.3389/fendo.2020.00288. PMID: 32582019.
• Chen 2021. Evaluation of the Bioequivalence of Acarbose in Healthy Chinese People. Clinical Pharmacology in Drug Development, 2021. DOI: 10.1002/cpdd.921. PMID: 33606918.
• Lobato 2026. Acarbose or Canagliflozin vs. Placebo to Ameliorate Post‐Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial. Diabetes, Obesity & Metabolism, 2026. DOI: 10.1111/dom.70611. PMID: 41810556.
• Xu 2020. Method for evaluating the human bioequivalence of acarbose based on pharmacodynamic parameters. The Journal of International Medical Research, 2020. DOI: 10.1177/0300060520960317. PMID: 33044102.
• Wang 2021. Acarbose for Postprandial Hypotension With Glucose Metabolism Disorders: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 2021. DOI: 10.3389/fcvm.2021.663635. PMID: 34095252.
• Madden 2025. The Effects of Acarbose on the Postprandial Hypotensive Response in Older Adults. Can J Aging, 2025. DOI: 10.1017/s0714980825100056. PMID: 40719030.
• Liao 2025. The gerotherapeutic drugs rapamycin, acarbose, and phenylbutyrate extend lifespan and enhance healthy aging in house crickets. bioRxiv preprint, 2025. DOI: 10.1101/2025.08.25.671822.
• Yu 2021. The Effects of Acarbose on Non-Diabetic Overweight and Obese Patients: A Meta-Analysis. Adv Ther, 2021. DOI: 10.1007/s12325-020-01602-9. PMID: 33421022.

Background References

Canonical reference values and methodological references cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Studenski 2011. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50-58. DOI: 10.1001/jama.2010.1923. PMID: 21205966.
• Cesari 2009. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health-related events. J Gerontol A Biol Sci Med Sci. 2009;64(7):772-779. DOI: 10.1093/gerona/glp012. PMID: 19349594.
• Perera 2006. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. J Am Geriatr Soc. 2006;54(5):743-749. DOI: 10.1111/j.1532-5415.2006.00701.x. PMID: 16696738.
• ADA 2024. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1). DOI: 10.2337/dc24-S006.
• WHO 2000. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. 2000. PMID: 11234459.
• Bohannon 1997. Bohannon RW. Comfortable and maximum walking speed of adults aged 20-79 years: reference values and determinants. Age Ageing. 1997;26(1):15-19. DOI: 10.1093/ageing/26.1.15.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Anisimov 2008. Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773. PMID: 18728386.
• Tancredi 2015. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-1732. DOI: 10.1056/NEJMoa1504347. PMID: 26510021.
• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. (methodological reference) DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.